Chengdu Easton Biopharmaceuticals Co.,Ltd
- Country
- Ownership
- -
- Established
- 2009-06-01
- Employees
- 1.4K
- Market Cap
- -
- Website
- www.eastonpharma.cn
- Introduction
The company is a high-tech enterprise driven by R&D and innovation, integrating R&D, production and sales of chemical raw materials, high-end chemicals and biopharmaceuticals. The company was founded in 2009, has 8 wholly-owned subsidiaries, and currently employs more than 1,400 people. The company was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in September 2020. The company is a high-tech enterprise, driven by R&D and innovation, integrating the entire R&D, production and sales industry chain of chemical raw materials, high-end chemicals and biopharmaceuticals. The company's main products include high-end chemicals, small molecule innovative drugs, biopharmaceuticals, and APIs. Company honors: Sichuan Province Intellectual Property Strong Enterprise Cultivating Enterprise, 2022 Sichuan Health Industry Outstanding Enterprise, 2022 Sichuan Enterprise Top 20 Enterprise with the Most Potential for Technological Innovation and Development, 2022 Top 100 Sichuan Enterprises with Invention Patents, 2022 Best Industrial Enterprise in China Pharmaceutical R&D Product Line, 2022 Honorary Title of “Quality Craftsman Enterprise” in the Chinese Pharmaceutical Industry, “National Technological Innovation Demonstration Enterprise” and “National Green Factory”, “2022 China's Top 100 Pharmaceutical Innovation Enterprises”, etc.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
76
Drug Approvals
Diprophylline Injection
- Product Name
- 二羟丙茶碱注射液
- Approval Number
- 国药准字H20253579
- Approval Date
- Mar 11, 2025
Vecuronium Bromide for Injection
- Product Name
- 注射用维库溴铵
- Approval Number
- 国药准字H20253159
- Approval Date
- Jan 14, 2025
Ruxolitinib Phosphate Tablets
- Product Name
- 磷酸芦可替尼片
- Approval Number
- 国药准字H20249398
- Approval Date
- Nov 15, 2024
Compound Glycyrrhizin Tablets
- Product Name
- 复方甘草酸苷片
- Approval Number
- 国药准字H20244585
- Approval Date
- Jul 30, 2024
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next